Nanobots Therapeutics
Innovative MotionTx platform enhancing drug delivery and accumulation in target cells for superior therapeutic efficacy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | €960k | Seed |
| Total Funding | 000k | ||
Related Content
Nanobots Therapeutics, accessible at nanobotstx.com, is a pioneering biotech startup focused on revolutionizing drug delivery systems. The company has developed the MotionTx platform, a cutting-edge technology designed to enhance the penetration and accumulation of therapeutic drugs in target cells. This platform aims to improve the efficacy of treatments by ensuring that drugs reach their intended destinations within the body more effectively.
Nanobots Therapeutics primarily serves the pharmaceutical industry, offering solutions that address significant challenges in drug delivery, particularly in the treatment of bladder cancer. Bladder cancer affects approximately 550,000 individuals annually and is notoriously difficult to treat due to the low permeability of the bladder lining and the constant flushing of the bladder by urine. The company's flagship program, NBT 101, targets non-muscle invasive bladder cancer (NMIBC), providing a safer and more effective therapy option.
The market Nanobots Therapeutics operates in is the biotech and life sciences sector, with a specific focus on nanomedicine and targeted drug delivery. The company's business model involves collaborating with pharmaceutical companies and healthcare institutions to integrate their MotionTx platform into existing and new therapeutic drugs. By licensing their technology and forming strategic partnerships, Nanobots Therapeutics generates revenue through licensing fees, milestone payments, and royalties on sales of drugs that utilize their platform.
In summary, Nanobots Therapeutics is at the forefront of developing innovative drug delivery solutions that enhance the effectiveness of treatments for challenging medical conditions like bladder cancer. Their MotionTx platform represents a significant advancement in the field of nanomedicine, offering new hope for patients and new opportunities for pharmaceutical companies.
Keywords: nanomedicine, drug delivery, MotionTx, bladder cancer, biotech, life sciences, therapeutic entities, pharmaceutical partnerships, targeted therapy, NMIBC.